Handelsbanken Fonder AB Has $1.17 Million Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Handelsbanken Fonder AB grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 26.9% during the fourth quarter, Holdings Channel reports. The firm owned 103,909 shares of the company’s stock after purchasing an additional 22,000 shares during the period. Handelsbanken Fonder AB’s holdings in Roivant Sciences were worth $1,167,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Mirabella Financial Services LLP increased its stake in shares of Roivant Sciences by 4.1% in the third quarter. Mirabella Financial Services LLP now owns 34,583 shares of the company’s stock worth $404,000 after purchasing an additional 1,362 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Roivant Sciences by 42.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock valued at $60,000 after acquiring an additional 1,608 shares during the period. VELA Investment Management LLC grew its stake in shares of Roivant Sciences by 8.8% in the fourth quarter. VELA Investment Management LLC now owns 32,386 shares of the company’s stock worth $364,000 after acquiring an additional 2,621 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Roivant Sciences during the fourth quarter worth $33,000. Finally, Sectoral Asset Management Inc. raised its stake in Roivant Sciences by 19.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 30,447 shares of the company’s stock valued at $356,000 after purchasing an additional 5,020 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $11.03 on Monday. The business has a 50 day simple moving average of $10.92 and a 200 day simple moving average of $10.37. Roivant Sciences Ltd. has a one year low of $8.06 and a one year high of $13.24. The company has a market capitalization of $8.89 billion, a PE ratio of 2.12 and a beta of 1.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million during the quarter, compared to analysts’ expectations of $30.72 million. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -1.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ROIV. Wolfe Research started coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price target on the stock. TheStreet upgraded Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th. Deutsche Bank Aktiengesellschaft raised their price objective on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group boosted their price objective on Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Bank of America raised their target price on Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.90.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.60% of the stock is currently owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.